Drug intelligence / Profile preview

UNC7713

Development stage: Preclinical
Lead developer: University of North Carolina at Chapel Hill
Modality: Small Molecules

Overview

UNC7713 is a first-in-class covalent antagonist of the M-phase phosphoprotein 8 (MPP8), an epigenetic reader protein that recognizes the histone-3-lysine-9-trimethyl (H3K9me3) region of target gene promoters. By disrupting MPP8 binding to H3K9me3, UNC7713 inhibits the recruitment of transcription factors associated with cell proliferation and metastasis. Developed by researchers at the University of North Carolina at Chapel Hill, the compound has demonstrated submicromolar potency in reducing cell viability, inhibiting migration, and inducing apoptosis in preclinical models of bladder cancer.

Targets

MPHOSPH8 (M-phase phosphoprotein 8)

Beyond the preview

Go deeper on UNC7713.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UNC7713.

Explore the full profile